Keyphrases
Adverse Events
100%
Postoperative Complications
100%
Event Severity
100%
Adult Spinal Deformity
100%
Postoperative Readmission
100%
Albumin
100%
Spine
100%
Cyclin-dependent Kinase 4 (CDK4)
100%
Real-world Effectiveness
100%
Metastatic Breast Cancer
100%
Estrogen Receptor-positive
100%
Palbociclib
100%
Ribociclib
80%
Abemaciclib
80%
Progression-free Survival
60%
Adult Spinal Deformity Surgery
50%
Median Progression-free Survival
40%
30-day Readmission
37%
90-day Readmission
37%
Postoperative Outcomes
25%
HER2-negative Breast Cancer
20%
Medical Council
20%
Second-line Treatment
20%
No Significant Difference
20%
Overall Survival
20%
Median Overall Survival
20%
Danish Context
20%
Overall Survival Analysis
20%
Inhibitor Treatment
20%
ER-positive
20%
Initial Treatment
20%
ASA Score
12%
Nutritional Status
12%
Multivariable
12%
Referral Center
12%
Risk Increase
12%
Revision Surgery
12%
Relative Risk
12%
Logistic Regression Analysis
12%
Single Center
12%
Comorbidity Burden
12%
Hemoglobin Level
12%
Statistical Significance
12%
Point Estimate
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Spine Malformation
100%
Postoperative Complication
100%
Palbociclib
100%
Metastatic Breast Cancer
100%
Progression Free Survival
100%
Abemaciclib
80%
Ribociclib
80%
Overall Survival
60%
Breast Cancer
20%
Acetylsalicylic Acid
16%
Comorbidity
16%
Medicine and Dentistry
Postoperative Complication
100%
Adverse Event
100%
Adult Spine Deformity
100%
Cyclin-Dependent Kinase
100%
Patient Referral
16%
Logistic Regression Analysis
16%
Acetylsalicylic Acid
16%
Nutritional Status
16%
